|
Neihu, Taiwan (February 23, 2021)
Abnova announced today it has introduced a pseudovirus neutralizing antibody test for COVID19, UK B1.1.7, and South African B1.351 variants for the post-vaccine era (http://www.abnova.com/products/products_detail.asp?catalog_id=KA6152). Several companies including Moderna, BioNtech, and Astrazeneca have received EUA approved for their vaccines. The vaccinated individual’s antibody response, specifically the neutralizing antibody titer, has become the new focus for detection and monitoring. Pseudovirus assay’s long track-record of safety and flexibility is the best alternative to live virus assay for measuring neutralizing antibody, which is distinct from the general IgM IgG antibody. The market potential for neutralizing antibody test is substantial.
Abnova’s neutralizing antibody test utilizes a combination of lentiviral pseudotyped vector with luciferase reporter gene and ACE2 transfected cell line 239T. This platform is a gold-standard neutralizing antibody measurement method regardless of the vaccine subtypes, ie mRNA, viral vector, protein and subunit vaccines. Massive scale vaccination is being deployed and implemented in each countries; several more vaccines are in the pipeline awaiting approval. Moreover, variant vaccines are in early phase of clinical trials. This will further catapult the market for neutralizing antibody testing.
A general IgM IgG antibody response from an COVID-19 infection or vaccination does not guarantee neutralizing antibody response which specifically block the interaction of COVID-19 and variant’s spike (S) and ACE2 proteins to prevent viral entry into cells. A protective immunity is the generation of neutralizing antibody which prevents future infection. Unfortunately, even a good neutralizing antibody will wane with time. Hence, routine checking and monitoring neutralizing antibody will become a necessity in the post-vaccine era. If the neutralizing antibody has decreased below a threshold, a booster vaccine will be needed. |
+886-2-87511888
sales@abnova.com
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products, and services relating to circulating rare cells, circulating exosomes, and circulating cell-free RNA for early to metastatic to recurrent disease and treatment diagnosis, prediction, guidance, and monitoring. Abnova facility is for proprietary bioreagent and high-throughput automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)